Phio Pharmaceuticals Corp (PHIO) concluded trading on Thursday at a closing price of $1.65, with 5.69 million shares of worth about $9.39 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -41.28% during that period and on April 10, 2025 the price saw a gain of about 7.14%. Currently the company’s common shares owned by public are about 4.78M shares, out of which, 4.23M shares are available for trading.
Stock saw a price change of 41.03% in past 5 days and over the past one month there was a price change of 22.22%. Year-to-date (YTD), PHIO shares are showing a performance of -8.33% which decreased to -73.04% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.97 but also hit the highest price of $9.79 during that period. The average intraday trading volume for Phio Pharmaceuticals Corp shares is 8.53 million. The stock is currently trading 28.28% above its 20-day simple moving average (SMA20), while that difference is up 9.80% for SMA50 and it goes to -39.92% lower than SMA200.
Phio Pharmaceuticals Corp (NASDAQ: PHIO) currently have 4.78M outstanding shares and institutions hold larger chunk of about 5.13% of that.
The stock has a current market capitalization of $7.89M and its 3Y-monthly beta is at 0.98. It has posted earnings per share of -$10.33 in the same period. It has Quick Ratio of 5.65 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PHIO, volatility over the week remained 32.00% while standing at 11.88% over the month.
Stock’s fiscal year EPS is expected to rise by 147.36%.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on August 05, 2020 offering a Buy rating for the stock and assigned a target price of $4 to it.
